RJFSA
KERX

Raymond James Financial Services Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,428
Closed -$39K – 2956
2018
Q3 		$39K Sell
11,428
-3,367
-23% -$12.1K ﹤0.01% 2729
2018
Q2 		$56K Sell
14,795
-1,990
-12% -$9.69K ﹤0.01% 2667
2018
Q1 		$69K Buy
16,785
+200
+1% +$931 ﹤0.01% 2422
2017
Q4 		$77K Sell
16,585
-940
-5% -$5.18K ﹤0.01% 2405
2017
Q3 		$124K Buy
17,525
+1,030
+6% +$7.41K ﹤0.01% 2367
2017
Q2 		$119K Buy
16,495
+5,628
+52% +$35.2K ﹤0.01% 2322
2017
Q1 		$67K Buy
+10,867
New +$59.5K ﹤0.01% 2295

Raymond James Financial Services Advisors's KERX Position: Q4 2018 in Review

Raymond James Financial Services Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 11,428 shares — an estimated $39K sold.

Raymond James Financial Services Advisors first reported a position in KERX in Q1 2017 and held it in 7 quarters. The position peaked at $124K in Q3 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

  • Raymond James Financial Services Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 11,428 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $39K.
  • Raymond James Financial Services Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q1 2017 and held it in 7 quarters.
  • Raymond James Financial Services Advisors's Keryx Biopharmaceuticals Inc position peaked at $124K in Q3 2017.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.